Abstract
Behaviorally, sigma1 agents modulate opioid analgesia. To examine possible mechanisms responsible for these interactions, we have identified a cell line containing both sigma1 and opioid receptors. [3H](+)-pentazocine binding in BE(2)-C human neuroblastoma cells is high affinity (KD 3.4 +/- 0.7 nM) and high density (Bmax 2.98 +/- 0.14 pmol/mg protein). Competition studies reveal a selectivity profile similar to that of sigma1 sites in guinea pig brain. (+)-Pentazocine has no effect upon either basal or forskolin-stimulated cyclase in the BE(2)-C cells, but cAMP accumulation is inhibited by the morphine, DPDPE and naloxone benzoylhydrazone. (+)-Pentazocine at concentrations as high as 10 microM does not affect this opioid effect, implying that sigma1/opioid interactions are not mediated at the level of the cell. This suggest that their behavioral interactions result from interacting neural circuits. Although (+)-pentazocine is without effect in the cyclase system, it does block carbachol-stimulated phosphoinositol turnover (IC50 6.5 +/- 1.14 microM). The specificity of the effect is confirmed by the ability of haloperidol (1 microM) to shift the IC50 value of (+)-pentazocine 2-fold to the right.
References
Nov 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·A J BlumeG Boone
Feb 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·S K SharmaW A Klee
Jan 1, 1992·Life Sciences·E M CostaG H Loew
Mar 1, 1992·Trends in Pharmacological Sciences·R QuirionD P Taylor
May 22, 1992·Brain Research·J M WalkerB DeCosta
Jan 1, 1992·Glia·A Georg, A Friedl
Jul 1, 1991·Neuropharmacology·G Z ZhouD Rodbard
Jan 1, 1991·Advances in Experimental Medicine and Biology·E W Karbon, S J Enna
Jun 1, 1990·Trends in Pharmacological Sciences·C Chavkin
Nov 1, 1990·Journal of Neurochemistry·S M CanduraL G Costa
Sep 17, 1990·Brain Research·S B Hellewell, W D Bowen
Apr 25, 1989·European Journal of Pharmacology·W D BowenK A McGarry
Jan 1, 1989·Life Sciences·J M MusacchioP D Canoll
Jul 17, 1989·FEBS Letters·B R de CostaK C Rice
May 30, 1989·European Journal of Pharmacology·Z W YangJ C Byrd
Dec 1, 1973·Biochemical Pharmacology·Y Cheng, W H Prusoff
Nov 1, 1984·Endocrinology·E A Frey, J W Kebabian
Jul 27, 1981·Life Sciences·G A Weiland, P B Molinoff
Sep 15, 1982·The Biochemical Journal·M J BerridgeM R Hanley
May 5, 1995·Neuroscience Letters·C C Chien, G W Pasternak
Jan 15, 1993·European Journal of Pharmacology·B J Vilner, W D Bowen
Nov 30, 1993·European Journal of Pharmacology·C C Chien, G W Pasternak
Dec 27, 1995·European Journal of Pharmacology·C C Chien, G W Pasternak
Citations
Jul 4, 2001·Biochemical Pharmacology·J Mei, G W Pasternak
Nov 18, 2000·European Journal of Pharmacology·W Hong, L L Werling
Sep 6, 2002·Pharmacology, Biochemistry, and Behavior·S M RawlsMartin W Adler
Jan 22, 2010·Molecular Pharmacology·Felix J KimGavril W Pasternak
Jun 10, 2015·Journal of Receptor and Signal Transduction Research·Colin G Rousseaux, Stephanie F Greene
Feb 28, 2002·The Journal of Pharmacology and Experimental Therapeutics·Jianfeng Mei, Gavril W Pasternak
Sep 6, 2013·Molecular Pharmacology·Joel M SchrockFelix J Kim
Sep 14, 2006·Pharmacological Reviews·Ting-Chao Chou
Mar 30, 2017·PloS One·Ling PanYing-Xian Pan
Nov 7, 2019·Frontiers in Pharmacology·Halley M OyerFelix J Kim
May 10, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Magali ToussaintPeter Brust
Feb 27, 2017·Cancer Research·Jeffrey D ThomasFelix J Kim
Aug 4, 2004·Cancer Research·Ebru AydarMustafa B A Djamgoz